Dr. Lee, Chi-Ho Paul reconceptualizes obesity as a chronic, multifactorial disease central to cardiovascular-kidney-metabolic (CKM) syndrome. He advocates risk-stratified management beyond BMI, emphasizing adipose dysfunction and inflammation. Highlighting dual GIP/GLP-1 receptor agonists, he outlines their durable efficacy in weight, metabolic, and CKM outcomes, redefining long-term obesity treatment strategies.

This lecture by Professor Christoph Wanner emphasizes the importance of early diagnosis and treatment of chronic kidney disease (CKD), particularly in patients with cardiovascular comorbidities, advocating for

In a recent lecture, Dr. Cheng Yuk Yan, Alice, emphasizes the importance of early and comprehensive screening for cardio-kidney-metabolic (CKM) syndrome. Dr. Cheng advocated for initiating empagliflozin early and noted that any specialist who recognizes the need should consider initiating it. This approach is supported by trials like the EMPA-REG OUTCOME, EMPA-KIDNEY, and the EMPEROR trials. These studies helped establish empagliflozin as a foundational "organ-protecting" therapy, which is now recommended in major international guidelines.

This lecture by Professor Adeera Levin emphasizes the urgent need for early detection and intervention in chronic kidney disease (CKD), noting that even mild cases require prompt action, including consideration of sodium-glucose co-transporter 2 (SGLT2) inhibitors like empagliflozin, which have demonstrated the potential to significantly delay kidney replacement therapy by over 26 years.